Formulation And Development Of Carbamazepine Transdermal Patches: In Vitro And Ex Vivocharacterization
Objective: The investigation's objective was to create and assess matrix-type transdermal drug delivery systems (TDDS) for carbamazepine (CBZ).
Experimental: The solvent evaporation process was used to create the matrix type TDDS of CBZ. Ten formulations were created, with the ratios of Eudragit RL 100 and Hydroxypropyl Methylcellulose in each formulation being 5:0, 4:1, 3:2, 2:3, and 1:4 for formulations A1, A2, A3, and A5, and the same for formulations B1, B2, B3, and B4. All formulations contained 15% v/w of propylene glycol as a plasticizer and 6% v/w of carvone as a penetration enhancer in a solvent system of dichloromethane and methanol. In vitro release, ex vivo permeability, moisture absorption, moisture content, and mechanical characteristics of the produced TDDS were assessed. Fourier Transform Infrared (FTIR) Spectroscopy was used to examine the physicochemical interactions between carbamazepine and polymers.
Results: As compared to the lowest values, the maximum drug release in 24 hours for A series formulations was 89.29% (A4) and for B series formulations was 86.17% (B5) (57.58 for A1 and 50.64 for B1). In both series, formulations A4 (flux 23.51 g/hr/cm2) and B5 (flux 22.98 g/hr/cm2) had the greatest skin permeability. The flux produced by formulations A4 and B5 is sufficient to produce the desired flux (19.10 g/hr/cm2). Tensile strength and elastic modulus measurements show that the formulations are strong but not brittle (3.42 kg/mm2 for A4 and 4.25 kg/mm2 for B5). The medication and the polymers did not interact in any way, according to FTIR measurements.
Conclusion: Carbamazepine matrix type transdermal therapeutic systems could be prepared with the required flux having suitable mechanical properties.